Rapt Therapeutics (NASDAQ:RAPT) Raised to Hold at Wall Street Zen

Key Points

• Rapt Therapeutics received an upgrade from a "sell" to a "hold" rating by Wall Street Zen, alongside mixed ratings from other analysts.
• The company's stock price has fluctuated significantly, with a 12-month low of $5.67 and a high of $27.84, and it recently opened at $13.31.
• Despite reporting a smaller-than-expected loss in its recent quarterly earnings, analysts project a consensus EPS of -2.14 for the current fiscal year.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

RAPT has been the topic of several other research reports. UBS Group reduced their price target on shares of Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Lifesci Capital upgraded shares of Rapt Therapeutics to a "strong-buy" rating and set a $31.00 price target on the stock in a research report on Tuesday. Finally, HC Wainwright boosted their price target on shares of Rapt Therapeutics to $27.00 and gave the company a "buy" rating in a research report on Thursday, July 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $21.67.

Rapt Therapeutics Trading Up 5.2%

Shares of NASDAQ:RAPT opened at $13.31 on Friday. The company has a market cap of $220.15 million, a price-to-earnings ratio of -0.69 and a beta of -0.09. The company has a 50-day moving average price of $8.88 and a 200-day moving average price of $8.74. Rapt Therapeutics has a 12 month low of $5.67 and a 12 month high of $27.84.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($2.48) by $1.84. As a group, research analysts forecast that Rapt Therapeutics will post -2.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Rapt Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of RAPT. Sei Investments Co. purchased a new stake in Rapt Therapeutics in the fourth quarter worth about $64,000. JPMorgan Chase & Co. grew its holdings in Rapt Therapeutics by 1,128.3% in the fourth quarter. JPMorgan Chase & Co. now owns 205,164 shares of the company's stock worth $324,000 after purchasing an additional 188,461 shares during the period. Geode Capital Management LLC grew its holdings in Rapt Therapeutics by 4.9% in the fourth quarter. Geode Capital Management LLC now owns 716,937 shares of the company's stock worth $1,133,000 after purchasing an additional 33,758 shares during the period. ADAR1 Capital Management LLC grew its holdings in shares of Rapt Therapeutics by 15,557.5% during the fourth quarter. ADAR1 Capital Management LLC now owns 1,174,313 shares of the company's stock valued at $1,855,000 after buying an additional 1,166,813 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Rapt Therapeutics by 25.5% during the fourth quarter. Renaissance Technologies LLC now owns 369,736 shares of the company's stock valued at $584,000 after buying an additional 75,136 shares during the last quarter. Hedge funds and other institutional investors own 99.09% of the company's stock.

About Rapt Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.